Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros












Base de dados
Intervalo de ano de publicação
1.
Rev Med Suisse ; 4(139): 18-20, 22-3, 2008 Jan 09.
Artigo em Francês | MEDLINE | ID: mdl-18251210

RESUMO

This review discuss several studies published in 2007 that will modify current therapeutic attitudes. New evidence confirm that antipsychotics increase mortality in demented elderly persons with behavioral symptoms. Unfortunately, donepezil was no more effective than placebo to treat agitation in these patients. Aspirine, nonsteroidal anti-inflammatories, as well as supplementation with folate, vitamines B6 and B12 did not prove beneficial to prevent cognitive decline. Hormonal substitution with DHEA, testosterone, and growth hormone is ineffective as anti-aging medicine, while calcium and vitamin d'effectiveness was confirmed in fracture prevention. Finally, several studies report prognostic information that will prove important to improve preparation plan for future heat wave.


Assuntos
Geriatria , Idoso , Humanos
2.
Ann Oncol ; 17(4): 578-83, 2006 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-16469752

RESUMO

BACKGROUND: Exclusive liver metastases occur in up to 40% of patients with uveal melanoma associated with a median survival of 2-7 months. Single agent response rates with commonly available chemotherapy are below 10%. We have investigated the use of fotemustine via direct intra-arterial hepatic (i.a.h.) administration in patients with uveal melanoma metastases. PATIENTS AND METHODS: A total of 101 patients from seven centers were treated with i.a.h. fotemustine, administered intra-arterially weekly for a 4-week induction period, and then as a maintenance treatment every 3 weeks until disease progression, unacceptable toxicity or patient refusal. RESULTS: A median of eight fotemustine infusions per patient were delivered (range 1-26). Catheter related complications occurred in 23% of patients; however, this required treatment discontinuation in only 10% of the patients. The overall response rate was 36% with a median overall survival of 15 months and a 2-year survival rate of 29%. LDH, time between diagnosis and treatment start and gender were significant predictors of survival. CONCLUSIONS: Locoregional treatment with fotemustine is well tolerated and seems to improve outcome of this poor prognosis patient population. Median survival rates are among the longest reported and one-third of the patients are still alive at 2 years.


Assuntos
Antineoplásicos/administração & dosagem , Neoplasias Hepáticas/tratamento farmacológico , Melanoma/tratamento farmacológico , Compostos de Nitrosoureia/administração & dosagem , Compostos Organofosforados/administração & dosagem , Neoplasias Uveais/tratamento farmacológico , Adulto , Idoso , Feminino , Humanos , Injeções Intra-Arteriais , Neoplasias Hepáticas/secundário , Masculino , Pessoa de Meia-Idade
3.
Rev Med Suisse Romande ; 120(11): 887-92, 2000 Nov.
Artigo em Francês | MEDLINE | ID: mdl-11140307

RESUMO

In elderly persons, hip fracture is frequent and associated with serious physical, functional and psychological consequences. Hip protectors seem promising for preventing hip fractures, especially in frail, institutionalized elderly persons. Despite methodological limitations, five randomized trials have reported positive results, with up to 85% risk fracture reduction in some trial. Interestingly, although 13 hip fractures occurred in subjects assigned to wear hip protector, only one occurred while the protector was actually worn. Adherence with wearing hip protectors remains a problem. Several ongoing trials will further enhance our knowledge on hip protectors effectiveness and cost-effectiveness to better define their role in hip fracture prevention.


Assuntos
Fraturas do Fêmur/prevenção & controle , Idoso Fragilizado , Equipamentos de Proteção/normas , Distribuição por Idade , Fatores Etários , Idoso , Fenômenos Biomecânicos , Análise Custo-Benefício , Desenho de Equipamento , Fraturas do Fêmur/etiologia , Humanos , Ensaios Clínicos Controlados Aleatórios como Assunto , Fatores de Risco
4.
Schweiz Med Wochenschr ; 128(48): 1906-9, 1998 Nov 28.
Artigo em Francês | MEDLINE | ID: mdl-9879619

RESUMO

To avoid the inflammatory syndrome generated by cardiopulmonary bypass, a new surgical technique, minimal invasive direct coronary artery bypass (MIDCAB), has been developed. An anastomosis is performed between the left internal mammary artery (LIMA) and the left anterior descending artery (LAD) on a beating heart, through a limited anterior thoracotomy. We describe our experience with this technique. Ten consecutive patients underwent a MIDCAB procedure. (9 males, age 65.9 +/- 9 years). There were 8 bypasses of the LIMA on the LAD, one bilateral mammary bypass on the LAD and the right coronary artery, and one conversion to a standard sternotomy with CPB for a saphenous vein bypass on the LAD because of injury to the LIMA (2nd case). There was one redo for haemostasis of the mammary artery bed (3rd case). The first 3 patients required postoperative blood transfusion. From the 4th operation onwards, with the introduction of new instrumentation which was better adapted to the narrowness of the surgical field, there were no further surgical complications. During the follow-up (mean 5 months; range 2-9), no patient suffered anginal recurrence. With the improvement of instrumentation, the MIDCAB technique offers satisfactory short- and mid-term results, while avoiding CPB with its adverse effects. Lastly, the cosmetic result is far better than with the conventional procedure.


Assuntos
Doença das Coronárias/cirurgia , Endoscópios , Anastomose de Artéria Torácica Interna-Coronária/instrumentação , Toracoscópios , Idoso , Desenho de Equipamento , Humanos , Masculino , Pessoa de Meia-Idade , Procedimentos Cirúrgicos Minimamente Invasivos/instrumentação , Avaliação de Processos e Resultados em Cuidados de Saúde
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...